Mirae Asset Global ETFs Holdings
MLYS icon

Mirae Asset Global ETFs Holdings’s Mineralys Therapeutics MLYS Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$957K Buy
35,510
+6,325
+22% +$174K ﹤0.01% 1657
2026
Q1 		$767K Buy
29,185
+3
+0% +$88 ﹤0.01% 1652
2025
Q4 		$1.05M Buy
29,182
+9,466
+48% +$380K ﹤0.01% 1487
2025
Q3 		$750K Sell
19,716
-4,521
-19% -$97.8K ﹤0.01% 1666
2025
Q2 		$328K Buy
24,237
+7,152
+42% +$104K ﹤0.01% 2024
2025
Q1 		$271K Buy
17,085
+702
+4% +$8.07K ﹤0.01% 2159
2024
Q4 		$202K Buy
16,383
+684
+4% +$8.94K ﹤0.01% 2382
2024
Q3 		$190K Buy
15,699
+5,937
+61% +$71.9K ﹤0.01% 2399
2024
Q2 		$114K Buy
+9,762
New +$123K ﹤0.01% 2505

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's MLYS Position: Q2 2026 in Review

Mirae Asset Global ETFs Holdings increased its Mineralys Therapeutics (MLYS) stake by 22% in Q2 2026, buying an estimated $174K and bringing the position to 35,510 shares worth $957K. The position accounts for ﹤0.01% of the portfolio, ranked #1657.

Mirae Asset Global ETFs Holdings first reported a position in MLYS in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.05M in Q4 2025. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Mirae Asset Global ETFs Holdings held 35,510 shares of Mineralys Therapeutics worth $957K as of Q2 2026.
  • Mirae Asset Global ETFs Holdings bought 6,325 Mineralys Therapeutics shares in Q2 2026, an estimated $174K.
  • Mineralys Therapeutics made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q2 2026, its #1657 holding.
  • Mirae Asset Global ETFs Holdings first reported a position in Mineralys Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • Mirae Asset Global ETFs Holdings's Mineralys Therapeutics position peaked at $1.05M in Q4 2025.
  • 224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.